Skip to content

What a Genome Kit Costs

Oak
Four terraced river pools at dawn, each holding glowing coiled organisms shining at increasingly bright intensities, with luminous seed pods along the banks.

“Genome kit price” resolves to four very different numbers. A benchtop DNA extraction kit such as Qiagen QIAamp, Thermo PureLink or a gSwab mini prep costs $30 to $350 for 50 to 300 preps. That is roughly $1 to $7 per sample of purified DNA and nothing else. A consumer whole-genome sequencing kit, where you mail saliva or a cheek swab and get files back, runs $300 to $1,000 depending on coverage and how much of that price is a report rather than sequencing. A clinical whole-genome test ordered through a physician and returned as an interpreted report is typically $1,500 to $5,000 in the United States. A full microcosting of sequencing inside a health system lands higher still. It counts the sample handling, the analysis pipeline, and the human interpretation time that consumer pricing hides 1.

If you are technically fluent and want your own data, the relevant comparison is the second and third tiers. The rest of this page explains what drives the spread and what you should require in exchange.

The four things sold under the word “kit”

A DNA extraction kit is a box of silica columns, lysis buffer and wash buffers, plus proteinase K. It converts tissue or blood into a tube of genomic DNA at maybe 20 to 100 ng/µL. It performs no sequencing. Pricing pages from Thermo and Qiagen are the reason searches for “genome kit price” surface $228 and $348 numbers that have nothing to do with reading a genome.

A consumer sequencing kit is a collection tube plus a prepaid return mailer plus a lane fraction on an Illumina or Ultima instrument. The collection hardware costs a few dollars. Almost all of the price is library preparation, sequencing consumables, compute, and margin.

A clinical test is the same wet lab work under a CLIA-certified laboratory. It adds sample chain of custody, confirmatory Sanger or orthogonal testing of reported variants, and a board-certified geneticist signing a report. The signature and the liability are a large part of what you pay for.

Finally, research and public health programs buy sequencing by the batch, where per-sample cost falls sharply with multiplexing. Programs sequencing pathogens have driven per-isolate costs down by pooling many samples per run and accepting lower per-sample depth 2. Hospital surveillance work has made the same point about batch design and run scheduling 3.

Coverage and library chemistry set the price

The dominant technical driver is how many bases you buy. A human genome is about 3.1 gigabases. Thirty-fold mean coverage therefore requires roughly 90 to 100 Gb of passing sequence. Fifteen-fold requires half that and costs close to half as much.

That difference is not cosmetic. At 30x with 150 bp paired-end reads you get reliable heterozygous single-nucleotide variant calls, usable small insertion and deletion calls, and enough signal for copy number and structural variant detection. At 15x, heterozygote sensitivity drops because a site covered by 8 reads can easily show 8 reference reads by chance. Vendors advertising “30x” sometimes mean raw yield before duplicate removal and quality filtering, which can leave you near 24x aligned. Ask for mean aligned coverage and the fraction of the callable genome above 10x.

At the low end of the spectrum, low-pass sequencing at 0.1x to 1x is a legitimate product for a narrow purpose. Clinical embryo aneuploidy screening works at that depth because whole-chromosome dosage needs very little data 4. It cannot genotype you. Understanding that the same word “sequencing” spans a 300-fold range in data volume explains most of the price confusion.

Library chemistry matters next. PCR-free libraries require more input DNA (typically 500 ng to 1 µg of high-molecular-weight material, which usually means blood rather than saliva) and cost more per sample. They repay this with even coverage in GC-extreme regions and far fewer duplicate reads. We prefer PCR-free from blood whenever a vendor offers it, because amplification artifacts are the failure mode you cannot fix downstream.

Instrument chemistry is the third driver and the one that has moved fastest. Newer sequencing-by-synthesis platforms have demonstrated consumable costs near a dollar per gigabase, which places the raw reagent cost of a 30x human genome around a hundred dollars at scale 5. Consumer prices sit above that because sample logistics and failed samples do not scale down the same way. Neither do compute, storage, and support.

What the sticker price leaves out

The gap between a $400 consumer kit and a $7,000 health system cost estimate is mostly labor. A careful microcosting study in a single United Kingdom center found that sequencing consumables were only one component of the total. Sample preparation, bioinformatics, and clinical interpretation contributed substantially 1. Health technology assessment work has repeatedly flagged the same problem, that the cost of a genomic test is not the cost of the assay but the cost of the whole diagnostic pathway 6.

Turnaround time is priced separately for the same reason. Rapid whole-genome sequencing for critically ill infants has been demonstrated end to end in about 26 hours, which requires dedicated instrument time and staff on call 7. You are paying for idle capacity.

Interpretation is the remaining cost, and it is the one consumers systematically underestimate. Sequencing a healthy adult produces thousands of rare variants, most of unknown significance, and only a small minority carry established clinical meaning 8. Incidental findings raise questions about disclosure, family members, and future reinterpretation that the analysis itself does not resolve 9. If you get a variant that looks consequential, take it to a clinical geneticist or a genetic counselor for confirmation in an accredited laboratory. Research-grade data is not a diagnosis.

What to require in exchange for the money

Insist on raw and portable files. A web dashboard is not a substitute. Specifically:

  • FASTQ or unaligned BAM with original base quality scores. If a vendor only ships a VCF, you cannot re-call, re-align to a new reference, or check anything.
  • An aligned CRAM against a named reference build, ideally GRCh38 with alt contigs handled explicitly, or a T2T-CHM13 alignment if offered. CRAM stores a 30x genome in roughly 15 to 25 GB versus 60 to 90 GB for BAM.
  • A gVCF rather than a sites-only VCF, so you can distinguish “reference” from “no data.”
  • QC metrics: mean aligned coverage, percent duplicates, insert size distribution, percent Q30, and a contamination estimate.

With those files, a reasonable self-check pass looks like this. Run samtools quickcheck on the CRAM first, because truncated transfers are the most common delivery failure. Compute coverage with mosdepth --by 1000 --fast-mode, and confirm that at least 95 percent of the non-N genome is above 10x. Check cross-sample contamination with verifyBamID2 or the VerifyBamID mode in DRAGEN, and treat an alpha above 0.02 as a reason to ask for a re-run. Confirm reported sex from chromosome X and Y coverage ratios before trusting anything else.

For variant calling, we would use DeepVariant with the WGS model on the delivered CRAM rather than GATK HaplotypeCaller, because it needs less parameter tuning and performs well on indels without a joint-calling cohort. Then normalize with bcftools norm -f GRCh38.fa -m -any before any annotation, since unnormalized indel representations silently break database lookups. Annotate with Ensembl VEP or bcftools csq, and keep the annotation version pinned, because interpretation changes over time and you will want to know which release produced a given call.

When the cheap option is the right one

If your goal is ancestry, pharmacogenomic haplotypes, or carrier status for well-characterized variants, a $400 30x consumer genome with raw file delivery is good value and will not be improved much by paying five times more. If your goal is anything with clinical weight, the marginal money buys accreditation, orthogonal confirmation, and a clinician, and cost-effectiveness analyses of genomic tests consistently show that value depends on what decision the result informs 10.

The one purchase we would avoid is a low-coverage kit sold as a whole genome. Fifteen-fold data feels like a bargain and then quietly fails you on heterozygous indels and structural variants. Buy fewer tests at full depth instead.

Footnotes

  1. Katharina Schwarze, James Buchanan, Jilles M. Fermont, et al. The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom. Genetics in Medicine, 2020. https://doi.org/10.1038/s41436-019-0618-7 ↩ ↩2

  2. Monica Vogel, Christian Utpatel, Caroline Corbett, et al. Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country. Scientific Reports, 2021. https://doi.org/10.1038/s41598-021-94297-z ↩

  3. Kady D. Waggle, Marissa Pacey Griffith, Alecia B. Rokes, et al. Methods for cost-efficient, whole genome sequencing surveillance for enhanced detection of outbreaks in a hospital setting. PLOS One, 2026. https://doi.org/10.1371/journal.pone.0355550 ↩

  4. Dagan Wells, Kulvinder Kaur, Jamie Grifo, et al. Clinical utilisation of a rapid low-pass whole genome sequencing technique for the diagnosis of aneuploidy in human embryos prior to implantation. Journal of Medical Genetics, 2014. https://doi.org/10.1136/jmedgenet-2014-102497 ↩

  5. Gilad Almogy, Mark Pratt, Florian Oberstrass, et al. Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform. 2022. https://doi.org/10.1101/2022.05.29.493900 ↩

  6. Katherine Payne, Martin Eden, Niall Davison, et al. Toward Health Technology Assessment of Whole-Genome Sequencing Diagnostic Tests: Challenges and Solutions. Personalized Medicine, 2017. https://doi.org/10.2217/pme-2016-0089 ↩

  7. Neil A. Miller, Emily G. Farrow, Margaret Gibson, et al. A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases. Genome Medicine, 2015. https://doi.org/10.1186/s13073-015-0221-8 ↩

  8. Noralane M. Lindor, Stephen N. Thibodeau, Wylie Burke. Whole-Genome Sequencing in Healthy People. Mayo Clinic Proceedings, 2017. https://doi.org/10.1016/j.mayocp.2016.10.019 ↩

  9. Wim Pinxten, Heidi Carmen Howard. Ethical issues raised by whole genome sequencing. Best Practice & Research Clinical Gastroenterology, 2014. https://doi.org/10.1016/j.bpg.2014.02.004 ↩

  10. Katherine Payne, Sean P. Gavan, Stuart J. Wright, et al. Cost-effectiveness analyses of genetic and genomic diagnostic tests. Nature Reviews Genetics, 2018. https://doi.org/10.1038/nrg.2017.108 ↩

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.